Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2002-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/01.ASN.0000032418.67267.F2PMID 12239236
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.

  2002cited by this paper
• Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes.

  2002cited by this paper
• Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

  2002cited by this paper
• Chelating Activity of Advanced Glycation End-product Inhibitors*

  2001cited by this paper
• Transition metals redox: reviving an old plot for diabetic vascular disease.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease.

  2001cited by this paper
• Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism.

  2000cited by this paper
• Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation.

  2000cited by this paper
• Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.

  2000cited by this paper
• Nitric oxide inhibits the formation of advanced glycation end products.

  2000cited by this paper
• Transition metal-catalyzed oxidation of ascorbate in human cataract extracts: possible role of advanced glycation end products.

  2000cited by this paper
• Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.

  1999cited by this paper
• Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications.

  1999cited by this paper
• The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation.

  1999cited by this paper
• Advanced Glycation End-Product Levels in Subtotally Nephrectomized Rats: Beneficial Effects of Angiotensin II Receptor 1 Antagonist Losartan

  1999cited by this paper
• 2‐Isopropylidenehydrazono‐4‐oxo‐thiazolidin‐5‐ylacetanilide (OPB‐9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage

  1999cited by this paper
• Carbonyl compounds cross‐link cellular proteins and activate protein‐tyrosine kinase p60c‐Src

  1999cited by this paper
• In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate.

  1998influential reference
• The S phase: Beginning, middle, and end: A perspective

  1998cited by this paper
• Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis.

  1998cited by this paper
• Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia.

  1998cited by this paper
• Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.

  1998cited by this paper
• Plasma level of pentosidine, an advanced glycation end product, in diabetic patients

  1998cited by this paper
• Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation

  1997influential reference
• In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs)

  1997cited by this paper
• Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammat

  1997cited by this paper
• The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis.

  1996cited by this paper
• Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis.

  1996cited by this paper
• Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits.

  1995cited by this paper
• Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis.

  1995cited by this paper
• Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose.

  1995cited by this paper
• Mechanism of Protein Modification by Glyoxal and Glycolaldehyde, Reactive Intermediates of the Maillard Reaction (*)

  1995cited by this paper
• Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist.

  1995cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1994cited by this paper
• Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.

  1993cited by this paper
• Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy.

  1992cited by this paper
• Pentosidine Formation in Skin Correlates With Severity of Complications in Individuals With Long-Standing IDDM

  1992cited by this paper
• Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen.

  1991cited by this paper
• Protein glycation and oxidative stress in diabetes mellitus and ageing.

  1991cited by this paper
• Role of Oxidative Stress in Development of Complications in Diabetes

  1991cited by this paper
• Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes.

  1991cited by this paper
• Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat

  1991cited by this paper
• Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging.

  1990cited by this paper
• Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process.

  1989cited by this paper
• Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

  1988cited by this paper
• Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein.

  1986cited by this paper
• Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.

  1986cited by this paper

• Pyridoxamine promotes heat-induced protein modifications in whey as evaluated by structure- and binding site-specific profiling using high-performance liquid chromatography-tandem mass spectrometry in scheduled multiple reaction mode.

  2025cites this paper
• Exploring the Therapeutic Role of Probiotics and Prebiotics in Mitigating Diseases Associated with Advanced Glycation End Products.

  2025cites this paper
• Telmisartan and/or vitamin D3 ameliorate skeletal muscle injury in a rat model of metabolic syndrome: A new insight into PPAR-γ/AT1 receptor/GLUT4 axis.

  2025cites this paper
• Vitamin B6 and diabetes and its role in counteracting advanced glycation end products.

  2024cites this paper
• Key Therapeutic Targets to Treat Hyperglycemia-Induced Atherosclerosis Analyzed Using a Petri Net-Based Model

  2023cites this paper
• Mitochondrial Fission as a Therapeutic Target for Metabolic Diseases: Insights into Antioxidant Strategies

  2023cites this paper
• A narrative review of exercise participation among adults with prediabetes or type 2 diabetes: barriers and solutions

  2023cites this paper
• Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products

  2023cites this paper
• Association between fingertip-measured advanced glycation end products and cardiovascular events in outpatients with cardiovascular disease

  2023cites this paper
• A Citrus and Pomegranate Complex Reduces Methylglyoxal in Healthy Elderly Subjects: Secondary Analysis of a Double-Blind Randomized Cross-Over Clinical Trial

  2023cites this paper
• Methylglyoxal in Cardiometabolic Disorders: Routes Leading to Pathology Counterbalanced by Treatment Strategies

  2023cites this paper
• The Effect of Treatment With Aminoguanidine, an Advanced Glycation End Product Inhibitor, on Streptozotocin-Induced Diabetic Rats and Its Effects on Physiological and Renal Functions

  2023cites this paper
• Advanced Glycation End-Products and Diabetic Neuropathy of the Retina

  2023cites this paper
• Blood and Tissue Advanced Glycation End Products as Determinants of Cardiometabolic Disorders Focusing on Human Studies

  2023cites this paper
• Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma

  2022cites this paper
• The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy

  2022cites this paper
• Telmisartan Mitigates High-Glucose-Induced Injury in Renal Glomerular Endothelial Cells (rGECs) and Albuminuria in Diabetes Mice.

  2021cites this paper
• Collagen crosslinking: effect on structure, mechanics and fibrosis progression

  2021cites this paper
• A review on prevention of glycation of proteins: Potential therapeutic substances to mitigate the severity of diabetes complications.

  2021cites this paper
• Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study

  2021cites this paper
• Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives

  2021cites this paper
• Skin autofluorescence is associated with progression of kidney disease in type 2 diabetes: A prospective cohort study from the Hong Kong diabetes biobank.

  2021cites this paper
• Natural Products as a Source of Inspiration for Novel Inhibitors of Advanced Glycation Endproducts (AGEs) Formation

  2021cites this paper
• Advanced Glycation End Products and Oxidative Stress in a Hyperglycaemic Environment

  2021cites this paper
• The association of coronary artery disease and advanced glycation end-products

  2021cites this paper
• Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes

  2020cites this paper
• Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.

  2020cites this paper
• Glycation in Disease

  2020cites this paper
• Keap1/Nrf2/ARE signaling unfolds therapeutic targets for redox imbalanced-mediated diseases and diabetic nephropathy.

  2020cites this paper
• Soluble RAGEs and cardiovascular risk factors in adult offspring of patients with premature coronary heart disease

  2020cites this paper
• Mechanistic Causes of Reduced Cardiorespiratory Fitness in Type 2 Diabetes

  2020influential citation
• Stochastic non-enzymatic modification of long-lived macromolecules - a missing hallmark of aging.

  2020cites this paper
• Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes.

  2019cites this paper
• Thiamine Supplementation is Beneficial as Adjunctive Therapy to ACE Inhibitors to Improve the Course of Nephrogenic Complications of Type II Diabetes Mellitus: Possible Involvement of the Inflammatory Cascade as a Mechanism of this Effect

  2019cites this paper
• Glycation of Plant Proteins: Regulatory Roles and Interplay with Sugar Signalling?

  2019cites this paper
• Methylglyoxal, a potent inducer of AGEs, connects between diabetes and cancer.

  2019cites this paper
• The Role for Protein Restriction in Addition to Renin-Angiotensin-Aldosterone System Inhibitors in the Management of CKD.

  2019cites this paper
• Association between Advanced Glycation End Products, Soluble RAGE Receptor, and Endothelium Dysfunction, Evaluated by Circulating Endothelial Cells and Endothelial Progenitor Cells in Patients with Mild and Resistant Hypertension

  2019cites this paper
• Towards multi-target antidiabetic agents: Discovery of biphenyl-benzimidazole conjugates as AMPK activators.

  2019cites this paper
• The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).

  2019cites this paper
• The Difference between the Therapeutic Effects of Thiamine & ACEI as Therapeutic Agents for the Control of Blood Glucose and ABP in Type II Diabetic Rats, A Comparative Study

  2018cites this paper
• Irbesartan attenuates advanced glycation end products‐mediated damage in diabetes‐associated osteoporosis through the AGEs/RAGE pathway

  2018cites this paper
• The clinical usefulness of glycated albumin in patients with diabetes and chronic kidney disease: Progress and challenges.

  2018cites this paper
• The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review

  2018cites this paper
• Dietary Metabolites and Chronic Kidney Disease

  2017cites this paper
• Therapeutic Agents Targeting at AGE-RAGE Axis for the Treatment of Diabetes and Cardiovascular Disease: A Review of Clinical Evidence

  2017cites this paper
• Arterial Stiffness in Chronic Kidney Disease

  2017cites this paper
• Association of Advanced Glycation End Products (AGEs) with Diabetic Nephropathy and Alcohol Consumption

  2017cites this paper
• Advanced Glycation End Products (AGEs) in Diabetic Complications

  2017cites this paper
• The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications

  2017cites this paper
• Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complication.

  2016cites this paper
• Autofluorescence cutanée des produits de glycation avancée (AGE), mémoire métabolique et complications du diabète

  2016cites this paper
• Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes

  2016cites this paper
• Advanced glycation end products in patients with peripheral artery disease

  2016influential citation
• Importance of Metabolic Memory in the Development of Vascular Complications in Diabetic Patients.

  2016cites this paper
• Effects of candesartan cilexetil and amlodipine orotate on receptor for advanced glycation end products expression in the aortic wall of Otsuka Long-Evans Tokushima Fatty (OETFF) type 2 diabetic rats

  2016cites this paper
• Edetate Disodium-Based Treatment for Secondary Prevention in Post-Myocardial Infarction Patients

  2016cites this paper
• Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways.

  2016cites this paper
• Chapter 6: Discussion

  2016cites this paper
• Retracted Article: Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line

  2016cites this paper
• Association of Skin Autofluorescence Levels With Kidney Function Decline in Patients With Peripheral Artery Disease

  2016cites this paper
• Uremic Toxicity of Advanced Glycation End Products in CKD.

  2016cites this paper
• Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy

  2016cites this paper
• Effects of candesartan cilexetil and amlodipine orotate on receptor for advanced glycation end products expression in the aortic wall of Otsuka Long-Evans Tokushima Fatty (OETFF) type 2 diabetic rats

  2016influential citation
• Diabetes mellitus and atrial fibrillation: Pathophysiological mechanisms and potential upstream therapies.

  2015cites this paper
• La memoria metabólica y las complicaciones cardiovasculares en el paciente diabético

  2015cites this paper
• Skin autofluorescence: a risk marker for chronic kidney disease

  2015cites this paper
• Cardiovascular Consequences of Obesity and Type 2 Diabetes Damaging effects of hyperglycemia on cardiovascular function : spotlight on glucose metabolic pathways

  2015cites this paper
• Olmesartan protects endothelial cells against oxidative stress-mediated cellular injury

  2015cites this paper
• Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications.

  2015cites this paper
• RETRACTED ARTICLE: Synergistic, cytotoxic and apoptotic activities of olmesartan with NF-κB inhibitor against HeLa human cell line

  2015cites this paper
• EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes

  2015cites this paper
• The progress of inflammation and oxidative stress in patients with chronic kidney disease

  2015cites this paper
• Renoprotection with antihypertensive effect by inhibition of rennin-angiotensin system

  2014cites this paper
• Regulation and therapeutic strategies of 4-hydroxy-2-nonenal metabolism in heart disease

  2014cites this paper
• Role of AGEs-RAGE system in cardiovascular disease.

  2014cites this paper
• Probucol for type 2 diabetes mellitus

  2014cites this paper
• Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies.

  2014cites this paper
• DW1029M, a novel botanical drug candidate, inhibits advanced glycation end-product formation, rat lens aldose reductase activity, and TGF-β1 signaling.

  2014cites this paper
• The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT)

  2014cites this paper
• Ramipril and Valsartan as Protective Agents against Some Complications of an Experimentally Induced Obesity in Rats

  2014cites this paper
• Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease

  2014cites this paper
• New Insight into the Molecular Drug Target of Diabetic Nephropathy

  2014cites this paper
• Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats

  2014cites this paper
• The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease.

  2014cites this paper
• Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?

  2014cites this paper
• Novel insights into metabolic sequelae of obstructive sleep apnoea: a link between hypoxic stress and chronic diabetes complications.

  2014cites this paper
• EVALUATION OF ANTIFIBROTIC AND ANTIOXIDANT EFFECTS OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II BLOCKER, ON EXPERIMENTALLY- INDUCED LIVER FIBROSIS IN RATS

  2014cites this paper
• Olmesartan Blocks Advanced Glycation End Products-Induced VCAM-1 Gene Expression in Mesangial Cells by Restoring Angiotensin-Converting Enzyme 2 Level

  2013cites this paper
• Reduction in advanced glycation end products by ACE inhibitor in diabetic cardiomyopathy model

  2013cites this paper
• Long-term hemodynamic and molecular effects persist after discontinued renin-angiotensin system blockade in patients with type 1 diabetes mellitus.

  2013cites this paper
• Effects of Angiotensin-Converting Enzyme Polymorphism on Soluble Receptor for Advanced Glycation End-Products in Maintenance Hemodialysis Patients

  2013cites this paper
• The renin-angiotensin system and advanced glycation end-products in diabetic retinopathy: impacts and synergies.

  2013cites this paper
• Skin Autofluorescence Reflects Integration of Past Long-Term Glycemic Control in Patients With Type 1 Diabetes

  2013cites this paper
• Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine.

  2013cites this paper
• Current therapeutic interventions in the glycation pathway: evidence from clinical studies

  2013cites this paper
• Aging: Drugs to Eliminate Methylglyoxal, a Reactive Glucose Metabolite, and Advanced Glycation Endproducts

  2012cites this paper
• Lipid Peroxidation and Antioxidants in Arterial Hypertension

  2012cites this paper
• The emerging challenge in diabetes: the "metabolic memory".

  2012cites this paper
• Advanced glycation end products in the plasma and renal tissues in experimental model of unilateral renal artery stenosis

  2012cites this paper